SUMMARY
This ASH 2016 report will focus on the diagnostic and prognostic utility of molecular abnormalities and on new treatment modalities in MDS. We selected 7 abstracts dealing with these topics.
(BELG J HEMATOL 2017;8(1):34–7)
By: D. Selleslag MD
This ASH 2016 report will focus on the diagnostic and prognostic utility of molecular abnormalities and on new treatment modalities in MDS. We selected 7 abstracts dealing with these topics.
(BELG J HEMATOL 2017;8(1):34–7)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
